Swiss Scientists Discover Mpox Brain Infection Risk

Swiss researchers have shattered the perception of Mpox as merely a skin-deep affliction. In a groundbreaking revelation published in Nature Communications, scientists from the University of Bern and the Institute of Virology and Immunology (IVI) have confirmed that the Mpox virus possesses the terrifying capability to infiltrate the human brain. This is not theoretical speculation; it is a confirmed biological reality that demands immediate attention from global health authorities.

While the world has grappled with the visible symptoms of the disease—painful rashes and flu-like exhaustion—this Swiss-led study exposes a far more insidious threat. The virus can actively infect brain cells, leading to direct neurological damage. This discovery fundamentally shifts the narrative surrounding Mpox, elevating it from a dermatological concern to a potential neurological crisis. As the virus continues to circulate globally, this critical insight from Bern serves as a stark warning: the impact of Mpox may extend far beyond what is visible to the naked eye.

The mechanism of the virus's attack is as fascinating as it is alarming. Utilizing advanced brain organoids—three-dimensional mini-brains cultivated from human stem cells—the research team observed the virus spreading relentlessly from cell to cell. The aftermath of this invasion mimics the devastation seen in some of the most feared neurodegenerative conditions known to medicine.

The infection triggers the formation of "neuritic beads"—bead-like thickenings along the nerve cells. This structural deformation is not a benign side effect; it is a harbinger of cell death. Strikingly, these same bead-like formations are hallmarks of Alzheimer's disease. By replicating this damage in the lab using a virus sample from the 2022 outbreak, the collaboration between the University of Bern, Lausanne University Hospital (CHUV), and the Spiez Federal Laboratory has provided irrefutable visual evidence of the virus's destructive potential within the central nervous system.

Historical data paints a grim picture that reinforces the urgency of these findings. A staggering 3% of all individuals infected with the Mpox virus between 1985 and 2021 developed serious neurological symptoms. We are not talking about mild headaches; these patients suffered from seizures and encephalitis, severe brain inflammation that can prove fatal.

For decades, the extent to which the virus affected the central nervous system remained a medical blind spot. The 3% figure represents a significant portion of the patient population, yet the biological drivers remained obscure until now. By connecting the historical statistical data with this new biological evidence of direct brain infection, Swiss scientists have closed a critical knowledge gap. This research validates the suffering of thousands of past patients and provides a crucial roadmap for monitoring current and future cases.

Amidst the alarming discoveries, the Swiss study delivers a powerful ray of hope. The research team did not stop at identifying the problem; they actively tested solutions. The antiviral drug Tecovirimat has emerged as a potent weapon against this neurological invasion. When treated with Tecovirimat, the infected brain organoids showed a significant reduction in viral load.

This finding is a game-changer for clinical treatment protocols. It suggests that existing antiviral therapies could be effective in protecting the brain from severe damage if administered correctly. As the University of Bern and the IVI emphasize, this is a victory not just for virology and neurobiology, but for public health strategy worldwide. Switzerland continues to lead the charge in medical innovation, providing the world with both the warning of the danger and the tools to fight it.